Biotech Stocks Surge as XBI Rallies 34% Since March

A Sector Snaps Back

Biotech investors are enjoying a rare stretch of good news after years of doldrums. The SPDR S&P Biotech ETF (XBI) has climbed roughly 34% since March, propelled by a wave of merger-and-acquisition activity and a string of positive clinical trial readouts, prompting at least one bullish call urging investors to buy into the rally rather than chase it later 1. The bounce has been broad enough to ripple into adjacent corners of the market, with reports noting that a surge in biotech shares helped lift broader tech futures even as some AI and software names lagged behind 6.

Winners Across the Value Chain

The upswing isn't confined to drugmakers themselves. Charles River Laboratories, which provides research and testing services to pharmaceutical companies, is drawing renewed attention from JPMorgan analysts who see its recent earnings as a signal that a broader biotech resurgence could keep lifting the stock, given its position as a bellwether for industry research spending 2. Actively managed funds are also capitalizing on the moment: the Franklin Biotechnology Discovery fund has posted a 13% annualized return over five years, more than double the return of a benchmark biotech index ETF, and portfolio managers are reportedly rotating into new names as the rally broadens 5.

Moderna has emerged as one of the marquee stories of the recovery. Favorable late-stage trial results for a cancer vaccine helped restore billionaire status to one of the company's co-founders, underscoring how a single clinical win can dramatically reshape personal and corporate fortunes in this sector 8. That same mRNA cancer vaccine program, developed jointly with Merck, features prominently in broader industry roundups covering FDA leadership questions and other pipeline news 4.

Caution Amid the Optimism

Not every headline is celebratory. Reporting on Huidagene has raised scrutiny over how the company disclosed a patient death connected to its therapy, a reminder that clinical setbacks and transparency failures remain real risks even as capital flows back into the sector 4. Separately, policy voices are warning that regulatory friction at the FDA could blunt America's competitive edge in regenerative medicine, with one former official arguing that bureaucratic delays are handing an advantage to international rivals, particularly China, at a moment when speed to market matters more than ever 7.

What It Means

Taken together, the coverage points to a sector inflection: M&A appetite, clinical breakthroughs, and fund inflows are converging to lift biotech valuations after a prolonged slump, with ongoing real-time tracking of FDA approvals and trial data expected to keep driving headlines into 2026 3. Yet the same reporting cycle shows the rally is uneven and fragile, dependent on trial outcomes, regulatory clarity, and corporate disclosure standards that remain under active examination.